Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
about
Are Astrocytes the Predominant Cell Type for Activation of Nrf2 in Aging and Neurodegeneration?Edaravone: a baby in the bathwater?Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis.Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis.Introduction to supplement: the current status of treatment for ALS.Symptom management in amyotrophic lateral sclerosis: We can do better.Edaravone, a Synthetic Free Radical Scavenger, Enhances Alteplase-Mediated Thrombolysis.Motor Neuron Gene Therapy: Lessons from Spinal Muscular Atrophy for Amyotrophic Lateral Sclerosis.Neuronal apoptosis inhibitory protein is implicated in amyotrophic lateral sclerosis symptoms.Proteinopathies and OXPHOS dysfunction in neurodegenerative diseases.Novel genes associated with amyotrophic lateral sclerosis: diagnostic and clinical implications.Discussing edaravone with the ALS patient: an ethical framework from a U.S. perspective.A biosensor-based framework to measure latent proteostasis capacity.Trajectories of impairment in amyotrophic lateral sclerosis: Insights from the Pooled Resource Open-Access ALS Clinical Trials cohort.How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis?A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.Edaravone and its clinical development for amyotrophic lateral sclerosis.Isogenic FUS-eGFP iPSC Reporter Lines Enable Quantification of FUS Stress Granule Pathology that Is Rescued by Drugs Inducing Autophagy.Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis.Pharmacokinetic profile of edaravone: a comparison between Japanese and Caucasian populations.TDP-43 self-interaction is modulated by redox-active compounds Auranofin, Chelerythrine and Riluzole.Serum uric acid levels in patients with amyotrophic lateral sclerosis: a meta-analysis.Inhibition of Drp1/Fis1 interaction slows progression of amyotrophic lateral sclerosis.Disease-modifying and symptomatic treatment of amyotrophic lateral sclerosis.Formulary Drug Review: Edaravone.Incorporating upper motor neuron health in ALS drug discovery.Ethics of clinical research in patients with ALS: is there a risk of exploitation?Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis.Exploratory double-blind, parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: Grade 3, requiring assistance for eating, excretion or ambulation).What can we learn from the edaravone development program for ALS?A Possible Role for Platelet-Activating Factor Receptor in Amyotrophic Lateral Sclerosis Treatment.Energy metabolism in ALS: an underappreciated opportunity?Correlating serum micrornas and clinical parameters in amyotrophic lateral sclerosis.Skeletal Muscle MicroRNAs as Key Players in the Pathogenesis of Amyotrophic Lateral Sclerosis.RNS60 exerts therapeutic effects in the SOD1 ALS mouse model through protective glia and peripheral nerve rescue.Patient-Derived iPSCs and iNs-Shedding New Light on the Cellular Etiology of Neurodegenerative Diseases.Pretreatment with the Free Radical Scavenger Edaravone Mitigates Kidney Glycogen Depletion and Neutrophil Infiltration after Leg Ischemia in a Rat Model: A Pilot Study.Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis.Safety and efficacy of human embryonic stem cell-derived astrocytes following intrathecal transplantation in SOD1G93A and NSG animal models.
P2860
Q41662736-8C1D98E3-EDB3-4F19-B50B-08F1C1AAC8B4Q42345783-4D35DB63-B31E-444A-B656-D5DB4A7594FDQ42687960-1B8B3010-F7DA-4C27-A20B-B1C6327AE564Q46084639-BBEE4A6D-7CAC-40CC-97FF-C9B0968E965AQ46135234-5BC22BD6-6AC2-4E59-84FC-14BB1302346EQ47102766-E2B85EBD-7EFB-472A-8044-C920D5D4153BQ47137226-FCBE7922-3322-4CFE-AF7E-364688B3067BQ47152662-439585F8-3801-432B-8C0C-7DA774D375C2Q47222540-33CA0890-1769-4F29-8061-8066F7C25B53Q47372795-865AF6D0-B755-4EE8-A871-E8769F84A27AQ47386842-C74B0F31-0416-4E58-BA95-951131AE3B1EQ47547271-D9576E2A-4121-4862-84D8-7128447F34C1Q47559156-C2CC1EDE-7C2B-414F-88F8-A69C9A3783A2Q47680014-D4BA5C08-419C-463F-A7D0-131FB2A28169Q47700268-A20A57BA-7218-4ECB-AE3C-E67EFCA6C1FCQ47782666-33A6BF71-09D2-4F3F-818D-B445CBE340C7Q47782687-28ADD3D2-1203-43DC-88C6-F913BBFE66E8Q47846621-1B06F2F4-B7DE-4A1F-92AE-A4270FBB48B4Q48033706-24187C89-1F68-4B38-9F60-F49BD881D9E4Q48033726-2C016E21-4D77-41EE-A8D7-DB0027C43514Q48112569-2655BEC0-A08B-4B6B-AD95-BFB0F7761A0AQ48216054-5B8C1F31-DD31-4493-AC7E-0E3A0ECBC151Q48240848-AE08F745-96D5-40B7-A161-390C488A0495Q49335981-7578F8EE-CE20-4FA5-A9A4-CE2A5A4B073AQ49587241-95B29C8E-0681-4F27-81C1-A963C7232F8DQ50055247-A227186C-D08D-4CD0-B0F6-C8E002DD63D2Q50197773-4F98ACAF-BBCC-4C2D-901F-248AB8B40CC1Q50222465-4DBC99E3-F42F-4213-AE05-E500864D6425Q50222471-279935FD-20BF-4743-8F86-AD40727470BBQ50222475-BE71585F-4EFD-4C91-ADA5-2384652022DCQ50222481-BCD7A72F-7521-4DD3-B669-6C33BFAFABC1Q50348976-48F68BED-4EE3-496D-9C83-68521ABF3FD0Q52651163-A0814EB9-C68E-4FAA-B521-5FA46F8863E8Q53512219-AA984388-E220-469D-970F-2946AF46E9B8Q54957895-26E39D4B-30AF-4BB2-81AE-32E10699097AQ55035170-E91696FE-AB61-4E55-905C-B22E18B5C74EQ55220858-9CBC5A77-349D-42EE-8BA5-A423CC5030AFQ55296386-ED51B63E-8B56-434C-925A-D7CD70FE588EQ55330301-CC43B99B-4305-4541-91FA-2F744BD79707Q55412795-3D1EB54C-AA35-4E94-8A85-CC850E0F200C
P2860
Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Safety and efficacy of edaravo ...... ind, placebo-controlled trial.
@en
type
label
Safety and efficacy of edaravo ...... ind, placebo-controlled trial.
@en
prefLabel
Safety and efficacy of edaravo ...... ind, placebo-controlled trial.
@en
P921
P1433
P1476
Safety and efficacy of edaravo ...... ind, placebo-controlled trial.
@en
P2093
Edaravone (MCI-186) ALS 19 Study Group
Writing Group
P304
P356
10.1016/S1474-4422(17)30115-1
P577
2017-05-15T00:00:00Z